Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Countryside and Community Research Institute Podcast: People, projects, process

How does research really happen? In this episode, we hear from CCRI Director, Matt Reed, and Business Manager, Chris Rayfield. Together with Aimee Morse, Research Assistant, they discuss the CCRI's dynamic, collaborative approach to research, exploring how the team work together to conduct and support a diverse range of projects

Countryside and Community Research Institute Podcast: Pride of Place(ment)

In this episode, we hear from this year's placement students Marie Steytler and Harry Batchelor. Marie and Harry joined us in September 2023 and have since immersed themselves within the collaborative and inclusive CCRI community. Join them as they discuss their placement experience so far with Nick Lewis, Research Assistant and Placement Coordinator, and learn more about the tasks they've been working on to support various CCRI research projects

Countryside and Community Research Institute Podcast: Doctoral Dialogues

In this episode, we hear from second-year PhD students Josh Davis and Annie Buckle. Tune in for an exclusive overview of the challenges and triumphs of pursuing doctoral research at CCRI - alongside the sage wisdom of senior research fellow (and CCRI postgraduate research lead) Daniel Keech. From navigating the intricacies of data analysis to finding inspiration in unexpected places, they share their insights, struggles, and moments of academic development in this research rendezvous

Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19

International audienc